CORRECTION article

Front. Pharmacol., 26 July 2023

Sec. Gastrointestinal and Hepatic Pharmacology

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1243304

Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology

  • 1. Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China

  • 2. Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu, China

  • 3. State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Linyi, China

Article metrics

View details

1

Citations

1,4k

Views

548

Downloads

Abstract

In the published article, there was an error in the Graphical Abstract as published. The number of weeks in the picture are incorrect. The Graphical Abstract has been corrected.

Additionally, a correction has been made to the section Abstract, subsection Methods, 2nd sentence. This sentence previously stated:

“In this study, C57BL/6J mice were fed a high-fat diet for 8 weeks, and the high-fat diet plus HRG or polyene phosphatidylcholine capsules were each administered by gavage for 4 weeks.”

The corrected sentence appears below:

“In this study, C57BL/6J mice were fed a high-fat diet for 10 weeks, and the high-fat diet plus HRG or polyene phosphatidylcholine capsules were each administered by gavage for 5 weeks.”

Lastly, a correction has been made to section Materials and Methods, subsection Animal Grouping and Model Establishment, 2nd and 3rd sentences. These sentences previously stated:

“After 12 consecutive weeks, relevant indicators were evaluated. Mice that passed the evaluation could be considered successful modeling, gavage at week 13, and sampled at week 17.”

The corrected sentences appear below:

“After 10 consecutive weeks, relevant indicators were evaluated. Mice that passed the evaluation could be considered successful modeling, gavage at week 12, and sampled at week 17.”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

nonalcoholic simple fatty liver, high-fat diet, intestinal flora disorder, 16S sequencing, network pharmacology

Citation

Liu Y, Tan Y, Huang J, Wu C, Fan X, Stalin A, Lu S, Wang H, Zhang J, Zhang F, Wu Z, Li B, Huang Z, Chen M, Cheng G, Mou Y and Wu J (2023) Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology. Front. Pharmacol. 14:1243304. doi: 10.3389/fphar.2023.1243304

Received

20 June 2023

Accepted

20 July 2023

Published

26 July 2023

Volume

14 - 2023

Edited and reviewed by

Ana Blas-García, University of Valencia, Spain

Updates

Copyright

*Correspondence: Guoliang Cheng, ; Yanfang Mou, ; Jiarui Wu,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics